Grundlæggende statistik
| CIK | 1629205 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Innovation1 Biotech Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 6, 2025 |
License Agreement dated October 29, 2024+ Exhibit 10.2 LICENSE AGREEMENT This License Agreement, made as of October 29, 2024 (the “Effective Date”), is by and among NLC Ltd., an Israeli limited company (“NLC Ltd.”), and NLC Viral Defense, LLC (“NLC LLC”), a Delaware limited liability company (collectively, “NLC” or “Licensor”), with principal offices located at 25 Shlomo Ben Yosef Street, Suite 44, Tel Aviv, Israel and Innovation) Biotech |
|
| May 6, 2025 |
Stock Issuance Agreement dated October 29, 2024+ Exhibit 10.1 STOCK ISSUANCE AGREEMENT This STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of October 29, 2024 (the “Effective Date”) by and between Innovation1 Therapeutics Corporation, a Delaware corporation (“Innovation1”) and NLC Ltd., an Israeli limited company (“NLC”). Innovation1 and NLC are collectively referred to herein as the “Parties.” RECITALS WHEREAS, subject to the terms and |
|
| May 6, 2025 |
Articles of Amendment (increase in authorized capital stock) Exhibit 3.1.14 ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION, AS AMENDED OF INNOVATION1 BIOTECH INC. Innovation1 Biotech Inc. (the ‘‘Company’’), a corporation organized and existing under the Revised Statutes of the State of Nevada (the ‘‘Nevada Revised Statutes’’), hereby certifies as follows: 1. Pursuant to Sections 78.385 and 78.390 of the Nevada Revised Statutes, the amendment herein set |
|
| May 6, 2025 |
Form of Leak-Out Agreement dated November 12, 2024 Exhibit 10.3 LEAK-OUT AGREEMENT November 12, 2024 This agreement (the “Leak-Out Agreement”) is being delivered to you in connection with an understanding by and between Innovation1 Biotech Inc., a Nevada corporation (the “Company”), and (the “Holder”). Reference is hereby made to the exchange agreement by and between the Holder and the Company dated November 12, 2024 (the “Exchange Agreement”), pu |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 INNOVATION |
|
| May 6, 2025 |
Form of Securities Purchase Agreement dated November 12, 2024+ Exhibit 10.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 1, 2024, between Innovation1 Biotech Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). Recitals A. The Company and the Purchasers |
|
| May 6, 2025 |
Form of Registration Rights Agreement dated November 12, 2024+ Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 1, 2024, between Innovation1 Biotech Inc., a Nevada corporation (the “Company”) and each of the several purchasers identified on the signature pages to the C Purchase Agreement (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the |
|
| May 6, 2025 |
Exhibit 3.1.13 FRANCISCO V. AGUILAR Secretary of State DEPUTY BAKKEDAHL Deputy Secretary for Commercial Recordings STATE OF NEVADA OFFICE OF THE SECRETARY OF STATE Commercial Recordings Division 401 N. Carson Street Carson City, NV 89701 Telephone (775) 684-5708 Fax (775) 684-7141 North Las Vegas City Hall 2250 Las Vegas Blvd North, Suite 400 North Las Vegas, NV 89030 Telephone (702) 486-2880 Fax |
|
| May 6, 2025 |
Exhibit 3.1.12 FRANCISCO V. AGUILAR Secretary of State DEPUTY BAKKEDAHL Deputy Secretary for Commercial Recordings STATE OF NEVADA OFFICE OF THE SECRETARY OF STATE Commercial Recordings Division 401 N. Carson Street Carson City, NV 89701 Telephone (775) 684-5708 Fax (775) 684-7141 North Las Vegas City Hall 2250 Las Vegas Blvd North, Suite 400 North Las Vegas, NV 89030 Telephone (702) 486-2880 Fax |
|
| May 6, 2025 |
Form of Exchange Agreement dated November 12, 2024+ Exhibit 10.6 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is dated this 12 day of November, 2024, by and between Innovation1 Biotech Inc., a Nevada corporation (the “Company”), and the undersigned holder (the “Holder”) of the Original Securities (defined below). WHEREAS, the Company desires to exchange all of the Series B Preferred Stock, Series B-1 Preferred Stock, promissory note |
|
| May 6, 2025 |
First Amendment to License Agreement and Stock Issuance Agreement Exhibit 10.1(a) First Amendment to License Agreement and Stock Issuance Agreement This first amendment (the “Amendment”) is made as of November 11, 2024, by and between Innovation) Biotech Inc., a Nevada corporation (“Innovation)”), and NLC Ltd., an Israeli limited company (“NLC Ltd.”), and NLC Viral Defense, LLC (“NLC LLC”), a Delaware limited liability company (collectively, “NLC”). Recitals: WH |
|
| February 27, 2025 |
Brio Financial Group Letter Agreement Exhibit 10.1 100 Somerset Corporate Blvd 2nd Floor Bridgewater Township, New Jersey 08807 January 8, 2025 Innovation 1 Biotech, Inc. 116 E 63rd St., Suite 300 New York, NY 10065 ATTN: Mr. Francis Knuettel II, Executive Chairman of the Board of Directors In order to document the understanding between as to the scope of the work that Brio Financial Group (“Brio” or “we”) will perform, as well as cer |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2025 INNOVATION1 BIOTECH INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-55852 82-2275255 (State of incorporation) (Commission File Number) (IRS Em |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement INNOVATION1 BIOTECH INC. |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 INNOVATION |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement INNOVATION1 BIOTECH INC. |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 INNOVATION1 BIOTECH |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-55852 CUSIP Number 39809D102 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For period ended: November 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 7, 2023 INNOVATION1 BIOTECH INC. |
|
| December 13, 2023 |
Form of Original Issue Discount Secured Convertible Promissory Note EXHIBIT 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| December 13, 2023 |
Form of Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 6, 2023, by and between Innovation1 Biotech Inc., a Nevada corporation (the “Company”), and each lender party that executes the signature page hereto as a purchaser (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth i |
|
| December 13, 2023 |
Form of Common Stock Purchase Warrant EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-55852 CUSIP Number 39809D102 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For period ended: August 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Trans |
|
| November 7, 2023 |
Form of Demand Promissory Note EXHIBIT 4.1 DEMAND PROMISSORY NOTE Principal: $20,000 Issuance Date: November 1, 2023 In exchange for receipt of $20,000, Innovation1 Biotech, Inc., a Nevada corporation (the “Company”) promises to pay to the order of Lincoln Park Capital, LLC (the “Holder”), the principal sum of $20,000 together with interest thereon from the date hereof, at 10% per annum, with interest and principal being immedi |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2023 INNOVATION1 BIOTECH INC. |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 INNOVATION1 BIOTECH INC. (Exact name of registrant as specified in its charter) Nevada 000-55852 82-2275255 (State or other jurisdiction (Commission (IRS Employer of |
|
| October 16, 2023 |
Form of Demand Promissory Note EXHIBIT 4.1 DEMAND PROMISSORY NOTE Principal: $20,000 Issuance Date: October 11, 2023 In exchange for receipt of $20,000, Innovation1 Biotech, Inc., a Nevada corporation (the “Company”) promises to pay to the order of Cavalry Fund I, LP (the “Holder”), the principal sum of $20,000 together with interest thereon from the date hereof, at 10% per annum, with interest and principal being immediately p |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 INNOVATION1 BIO |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 1, 2023 INNOVATION1 BIOTECH INC. |
|
| September 8, 2023 |
Form of Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August , 2023, by and between Innovation1 Biotech Inc., a Nevada corporation (the “Company”), and each lender party that executes the signature page hereto as a purchaser (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t |
|
| September 8, 2023 |
Form of Common Stock Purchase Warrant EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 8, 2023 |
Form of Original Issue Discount Secured Convertible Promissory Note EXHIBIT 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2023 INNOVATION1 BIOTECH INC. |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: May 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 INNOVATION |
|
| April 24, 2023 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 13, 2023, by and between Innovation1 Biotech Inc., a Nevada corporation (the “Company”), and each lender party that executes the signature page hereto as a purchaser (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in |
|
| April 24, 2023 |
EXHIBIT 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of November 29, 2022, between Innovation1 Biotech Inc., a Nevada corporation (the “Company”) (the Company and each other Person who becomes a party to this Agreement by execution of a joinder in the form of Exhibit A attached hereto, which |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 13, 2023 INNOVATION1 BIOTECH INC. |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: February 28, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 INNOVATION |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.000-55852 INNOVATION1 BIOTECH I |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2022 INNOVATION1 BIOTECH INC. |
|
| December 12, 2022 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 29, 2022, by and between Innovation1 Biotech Inc., a Nevada corporation (the ?Company?), and each lender party that executes the signature page hereto as a purchaser (each, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth |
|
| December 12, 2022 |
EXHIBIT 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) dated as of November 29, 2022, between Innovation1 Biotech Inc., a Nevada corporation (the ?Company?) (the Company and each other Person who becomes a party to this Agreement by execution of a joinder in the form of Exhibit A attached hereto, which |
|
| November 30, 2022 |
EXHIBIT 3.2 INNOVATION1 BIOTECH INC. a Nevada Corporation SECOND AMENDED AND RESTATED BYLAWS As Adopted November 18, 2022 - 1 - INNOVATION1 BIOTECH INC. (the ?Corporation?) SECOND AMENDED & RESTATED BYLAWS These Second Amended and Restated Bylaws have been approved by the Board of Directors of the Corporation and amend and restate the Amended and Restated Bylaws of the Corporation adopted on April |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2022 INNOVATION1 BIOTECH INC. |
|
| November 30, 2022 |
EXHIBIT 3.1 1 2 3 4 5 6 7 8 9 10 11 |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: August 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Trans |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2022 INNOVATION1 BIOTECH INC. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2022 INNOVATION1 BIOTECH INC. |
|
| November 14, 2022 |
Innovation1 Biotech Inc. Presentation dated November 14, 2022. EXHIBIT 99.1 |
|
| November 14, 2022 |
EXHIBIT 10.1 |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 19, 2022 INNOVATION1 BIOTECH INC. |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9, 2022 INNOVATION1 BIOTECH INC. |
|
| September 15, 2022 |
Innovation1 Biotech Appoints Frederick E. Pierce, II to its Board of Directors EXHIBIT 99.1 Innovation1 Biotech Appoints Frederick E. Pierce, II to its Board of Directors NEW YORK, September 15, 2022 ? Innovation1 Biotech Inc. (OTCQB: IVBT) (?Innovation1'' or the ?Company?), a small molecule drug discovery company focused on the clinical development of modified Schedule 1 molecules of botanical origin, today announced the appointment of Frederick E. Pierce, II, to its Board |
|
| August 15, 2022 |
EXHIBIT 99.1 Innovation1 Biotech Appoints Chief Scientific Officer Andrew L. Salzman, M.D. to its Board of Directors NEW YORK, August 11, 2022 ? Innovation1 Biotech Inc. (OTCQB: IVBT) (?Innovation1? or the ?Company?), a small molecule drug discovery company focused on the clinical development of modified Schedule 1 molecules of botanical origin, today announced the appointment of the Company?s Chi |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2022 INNOVATION1 BIOTECH INC. |
|
| August 15, 2022 |
EXHIBIT 99.2 |
|
| July 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 INNOVATION1 BIO |
|
| April 27, 2022 |
Innovation1 Biotech Inc. Presentation dated April 26, 2022. EXHIBIT 99.1 |
|
| April 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2022 INNOVATION1 BIOTECH INC. |
|
| April 21, 2022 |
EXHIBIT 10.2 MASTER SERVICES AGREEMENT This MASTER SERVICES AGREEMENT (?Agreement?) is entered into as of April 7, 2022 (the ?Effective Date?) by and between Salzman Group Ltd. with an address at 18 Hagat St., Kazrin 1290005, Israel together with its affiliates, Salzman Group, Inc., Salzman Investments Ltd., Salzman Group Pty. Ltd., Quitsa Pharmaceuticals Ltd., and Herring Creek Pharmaceuticals, I |
|
| April 21, 2022 |
EXHIBIT 10.3 |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 17, 2022 INNOVATION1 BIOTECH INC. |
|
| April 21, 2022 |
Dr. Andrew Salzman Employment Agreement filed April 21, 2022. EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of April 14, 2022 (the ?Effective Date?), by and between Dr. Andrew Salzman (the ?Employee?) and Innovation1 Biotech Inc., a Nevada corporation (the ?Company?) (collectively referred to herein as the ?Parties?). WHEREAS, the Company desires to employ the Employee on the terms and conditions se |
|
| April 18, 2022 |
Innovation1 Biotech Inc. Presentation. EXHIBIT 99.1 |
|
| April 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 18, 2022 INNOVATION1 BIOTECH INC. |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 10-Q 1 ivbtnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: February 28, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tran |
|
| April 15, 2022 |
Jeffrey Kraws employment agreement effective March 16, 2022 EXHIBIT 10.1 |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 INNOVATION |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 1, 2022 INNOVATION1 BIOTECH INC. |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2022 INNOVATION1 BIOTECH INC. |
|
| April 6, 2022 |
Innovation1 Biotech (IVBT) Completes Name and Ticker Symbol Change from Gridiron BioNutrients (GMVP) EXHIBIT 99.1 Innovation1 Biotech (IVBT) Completes Name and Ticker Symbol Change from Gridiron BioNutrients (GMVP) NEW YORK, April 4, 2022 ? Innovation1 Biotech Inc. (OTCQB: IVBT) (?Innovation1? or the ?Company?), a small molecule drug discovery company focused on the clinical development of modified Schedule 1 molecules of botanical origin, today announced it has completed the Company?s corporate |
|
| April 6, 2022 |
Articles of Amendment filed March 31, 2022 effective March 31, 2022 EX-3.1 2 ivbtex31.htm CERTIFICATE OF AMENDMENT TO CERTIFICATE EXHIBIT 3.1 |
|
| March 10, 2022 |
GRIDIRON BIONUTRIENTS, INC. 28,103,781 Shares of Common Stock 424B3 1 gmvp424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-262736 GRIDIRON BIONUTRIENTS, INC. 28,103,781 Shares of Common Stock This prospectus relates solely to the resale of up to an aggregate of 28,103,781 shares of our common stock, par value $0.001 per share (“Common Stock”), by the selling stockholders identified in this prospectus. The selling stockholders |
|
| March 8, 2022 |
Gridiron BioNutrients, Inc. 40 Wall Street, Suite 2701 New York, New York 10005 Gridiron BioNutrients, Inc. 40 Wall Street, Suite 2701 New York, New York 10005 March 8, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, DC 20549 Attention: Edward M. Kelly Re: Gridiron BioNutrients, Inc. Registration Statement on Form S-1/A File No. 333-262736 Ladies and Gentlemen: Pursuant to Rule 461 o |
|
| March 8, 2022 |
Registration No. 333-262736 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 2834 82-2275255 (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) (PRIMARY STANDARD INDUSTRIAL CLASSIFICATION C |
|
| March 8, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) GRIDIRON BIONUTRIENTS, INC. |
|
| February 15, 2022 |
Amendment to Purchase Agreement by and between Ingenius Biotech S.L. and Gridiron BioNutrients, Inc. EXHIBIT 10.12 |
|
| February 15, 2022 |
EXHIBIT 10.11 |
|
| February 15, 2022 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Gridiron Ventures, Inc., a Nevada corporation incorporated on July 20, 2017, is wholly owned by Gridiron BioNutrients, Inc. |
|
| February 15, 2022 |
EX-FILING FEES 6 gmvpex107.htm EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) GRIDIRON BIONUTRIENTS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offerin |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 2834 82-2275255 (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) (PRIMARY STANDARD INDUSTRIAL CLASSIFICATION CODE NUMBER) (I.R.S. EMPLOYER IDENTIFICATION NUMBE |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 9, 2022 GRIDIRON BIONUTRIENTS, INC. |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 2 (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 00 |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 00 |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 gmvp10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 10-Q 1 gmvpnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: November 30, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tran |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c‑5(d)(2)) ☒ Definitive Information Statement GRIDIRON BIONUTRIENTS, INC. (Name of |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c‑5(d)(2)) ☐ Definitive Information Statement GRIDIRON BIONUTRIENTS, INC. (Name of |
|
| January 3, 2022 |
8-K 1 gmvp8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 1, 2022 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55852 36-4797193 (State or other jurisdiction of i |
|
| December 22, 2021 |
8-K 1 gmvp8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 20, 2021 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55852 36-4797193 (State or other jurisdiction of |
|
| December 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 GRIDIRON BIONUTRIENT |
|
| December 10, 2021 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT GridIron Ventures, Inc., a Nevada corporation |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(f) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14f-1 THEREUNDER GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its corporate charter) Commission File No.: 000-55852 Nevada 36-4797193 (State or other jurisdiction of incorporation or organizat |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: August 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Trans |
|
| November 29, 2021 |
EXHIBIT 3.2 |
|
| November 29, 2021 |
EX-3.1 2 gmvpex31.htm AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS EXHIBIT 3.1 |
|
| November 29, 2021 |
8-K 1 gmvp8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 24, 2021 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55852 36-4797193 (State or other jurisdiction of |
|
| November 29, 2021 |
EX-10.1 4 gmvpex101.htm SERIES B-1 PURCHASE AGREEMENT EXHIBIT 10.1 EXECUTION COPY SERIES B-1 PURCHASE AGREEMENT THIS SERIES B-1 PURCHASE AGREEMENT (the “Agreement”) is made as of the 24th day of November 2021 by and between Gridiron Nutrients, Inc., a Nevada corporation (the “Company”), and the Purchaser signatory hereto (the “Purchaser”). WHEREAS, the Company has authorized a series of convertibl |
|
| November 15, 2021 |
8-K 1 gmvp8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2021 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55852 36-4797193 (State or other jurisdiction of |
|
| November 15, 2021 |
Lock-up/Leak-Out Agreement dated November 9, 2021 EXHIBIT 10.1 LOCK-UP/LEAK-OUT AGREEMENT THIS LOCK-UP/LEAK-OUT AGREEMENT (the ?Agreement?) is made and entered into as of this 9th day of November 2021 (the ?Effective Date?) by and between Gridiron BioNutrients, Inc., a Nevada corporation (the ?Company?), and Jason Frankovich (the ?Shareholder?). For all purposes of this Agreement, the term ?Shareholder? shall include any and all affiliates (as de |
|
| November 8, 2021 |
8-K 1 gmvp8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 28, 2021 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55852 36-4797193 (State or other jurisdiction of |
|
| November 8, 2021 |
Definitive Asset Purchase Agreement with ST Biosciences, Ltd Dated November 5, 2021 EX-10.1 2 gmvpex101.htm AMENDED AND RESTATED ASSET PURCHASE AGREEMENT EXHIBIT 10.1 AMENDED AND RESTATED ASSET PURCHASE AGREEMENT THIS AMENDED AND RESTATED ASSET PURCHASE AGREEMENT (the “Agreement”) is entered into as of November 5, 2021, by and between GRIDIRON BIONUTRIENTS, INC., a Nevada corporation (“Purchaser”), ST BIOSCIENCES, LTD., a company organized under the laws of England and Wales (“Se |
|
| September 10, 2021 |
EX-3.1 2 gmvpex31.htm SERIES A WITHDRAWAL EXHIBIT 3.1 |
|
| September 10, 2021 |
EX-3.2 3 gmvpex32.htm SERIES B WITHDRAWAL EXHIBIT 3.2 |
|
| September 10, 2021 |
Certificate of Designations, Preferences and Rights of the Series B-1 Convertible Preferred Stock EX-3.3 4 gmvpex33.htm CERTIFICATE OF DESIGNATIONS EXHIBIT 3.3 |
|
| September 10, 2021 |
8-K 1 gmvp8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 7, 2021 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55852 36-4797193 (State or other jurisdiction of |
|
| September 10, 2021 |
EXHIBIT 10.1 |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 gmvp10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| April 16, 2021 |
EX-3.18 2 gmvpex318.htm CERTIFICATE OF DESIGNATION EXHIBIT 3.18 |
|
| April 16, 2021 |
8-K 1 gmvp8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 12, 2021 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55852 36-4797193 (State or other jurisdiction of in |
|
| April 14, 2021 |
10-Q 1 gmvp10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| April 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2021 GRIDIRON BIONUTRIENTS, INC. |
|
| April 12, 2021 |
EX-10.1 2 gmvpex101.htm EXCHANGE AGREEMENT EXHIBIT 10.1 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 9th day of April, 2021 by and between Gridiron Nutrients, Inc., a Nevada corporation (the “Company”), and the holder signatory hereto (the “Holder”). WHEREAS, the Holder has from time to time previously acquired from the Company certain of the Company’s securities |
|
| January 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 GRIDIRON B |
|
| January 11, 2021 |
Articles of Amendment filed December 22, 2020 effective January 8, 2021 EXHIBIT 3.1.8 |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2021 GRIDIRON BIONUTRIENTS, INC. |
|
| December 15, 2020 |
Calvary Convertible Note Dated January 27, 2020 EXHIBIT 10.6 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER US $555,000 - Principal US |
|
| December 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 GRIDIRON BIONUTRIENT |
|
| December 15, 2020 |
Calvary Convertible Note Dated April 27, 2020 EXHIBIT 10.7 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER US $259,615.35 - Principal |
|
| December 15, 2020 |
SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT GridIron Ventures, Inc., a Nevada corporation |
|
| December 15, 2020 |
Calvary Convertible Note Dated November 25, 2019 EXHIBIT 10.5 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER US $140,000 - Principal US |
|
| December 15, 2020 |
Calvary Convertible Note Dated August 27, 2019 EXHIBIT 10.4 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER US $30,000 - Principal US |
|
| December 15, 2020 |
Collaboration Agreement, Notis Global, Inc. January 24, 2020 EXHIBIT 10.3 COLLABORATION AGREEMENT This Collaboration Agreement (this “Agreement”) is made as of January 24, 2020, by and between Notis Global, Inc. (“NGBL”), and GridIron BioNutrients, Inc. (“GMVP”). 1. Collaboration Relationship. During the term of this Agreement, the parties will collaboratively explore and consider potential business opportunities for the parties within various segments of t |
|
| December 15, 2020 |
Toll Processing Agreement, Syndicate Oil, November 26, 2019 EXHIBIT 10.2 |
|
| December 15, 2020 |
Securities Purchase Agreement & Warrants Dated July 30, 2018 EXHIBIT 4.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), is entered into as of July 30, , 2018 (the “Execution Date”), by and among Gridiron BioNutrients, Inc., a Nevada corporation, with headquarters located at 1119 West 1st Ave., Ste. G, Spokane, Washington 99021 (the “Company”), and the investors listed on the Schedule of Buyers attached hereto (individual |
|
| December 15, 2020 |
Supply Agreement, Notis Global, Inc. November 27, 2019 EXHIBIT 10.1 SUPPLY AGREEMENT This Agreement (“the Agreement”), is made by and between EWSD 1, LLC, d/b/a/ SHI FARMS (“Shi Farms”), a Delaware limited liability company and Gridiron BioNutrients, Inc, a Nevada Corporation (“Gridiron”) , each individually “a Party,” and collectively, “the Parties.” WHEREAS Shi Farms grows industrial hemp and wishes to sell hemp biomass (“Product”); and Gridiron wis |
|
| December 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No.) Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement GRIDIRON BIONUTRIENT |
|
| December 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: August 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Trans |
|
| November 25, 2020 |
GRIDIRON BIONUTRIENTS, INC. 6991 East Camelback Road Suite D-300 Scottsdale, AZ 85251 CORRESP November 25, 2020 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.W. Washington, D.C. 20549 Re: GridIron BioNutrients, Inc. (the “Company”) Preliminary Proxy Statement on Schedule 14C Filed November 13, 2020 File No. 000-55852 Ladies and Gentlemen: The Company is in |
|
| November 13, 2020 |
GRIDIRON BIONUTRIENTS, INC. 6991 East Camelback Road Suite D-300 Scottsdale, AZ 85251 GRIDIRON BIONUTRIENTS, INC. 6991 East Camelback Road Suite D-300 Scottsdale, AZ 85251 Telephone: (800) 570-0438 ‘CORRESP’ November 13, 2020 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.W. Washington, D.C. 20549 Re: GridIron BioNutrients, Inc. (the “Company”) File No. 000-55852 Preliminary information statement on Schedule 14C Ladies and Gentlemen: This co |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No.) Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement GRIDIRON BIONUTRIENT |
|
| July 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 GRIDIRON BIONUT |
|
| July 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K x Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: May 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| May 5, 2020 |
22% Original Issue Discount Self Amortizing Convertible Note Due February 15, 2021. EX-4.1 2 gmvpex41.htm 22% ORIGINAL ISSUE DISCOUNT SELF AMORTIZING EXHIBIT 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES |
|
| May 5, 2020 |
QSI Holding Company, a Delaware Corporation Warrant to Purchase Stock, dated April 29, 2020 EX-10.2 4 gmvpex102.htm QSI HOLDING COMPANY, A DELAWARE CORPORATION EXHIBIT 10.2 |
|
| May 5, 2020 |
EXHIBIT 10.1 |
|
| May 5, 2020 |
8-K 1 gmvp8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2020 Gridiron BioNutrients, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55 |
|
| April 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 GRIDIRON B |
|
| April 13, 2020 |
GMVP / Gridiron BioNutrients, Inc. NT 10-Q - - NT 10-Q NT 10-Q 1 gmvpnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K x Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: February 29, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tran |
|
| March 10, 2020 |
GMVP / Gridiron BioNutrients, Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on March 10, 2020 Registration No. |
|
| February 5, 2020 |
EXHIBIT 10.6 STOCK PURCHASE AGREEMENT THIS AGREEMENT is made and entered into this 28th day of January 2020, by and between Gridiron BioNutrients, Inc. (“Purchaser”) and Grays Peak Ventures (“Seller”) with regard certain capital stock of Gridiron BioNutrients, Inc. a Nevada corporation (“Corporation”). WHEREAS, the Seller is the record owner and holder of certain issued and outstanding shares of c |
|
| February 5, 2020 |
EXHIBIT 10.2 COLLABORATION AGREEMENT This Collaboration Agreement (this “Agreement”) is made as of January 24, 2020, by and between Notis Global, Inc. (“NGBL”), and GridIron BioNutrients, Inc. (“GMVP”). 1. Collaboration Relationship. During the term of this Agreement, the parties will collaboratively explore and consider potential business opportunities for the parties within various segments of t |
|
| February 5, 2020 |
EX-10.4 6 gmvpex104.htm AMENDED AND RESTATED PROMISSORY NOTE EXHIBIT 10.4 EWSD 1, LLC d/b/a SHI FARMS AMENDED AND RESTATED 12.5% ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE THIS AMENDED AND RESTATED 12.5% ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THIS AMENDED AND RESTATED |
|
| February 5, 2020 |
EX-99.1 9 gmvpex991.htm PRESS RELEASE EXHIBIT 99.1 Gridiron BioNutrients enters into a Collaboration Agreement and executes a Biomass Supply Agreement Further Advancing its Expansion into the CBD Oil Market (February 5, 2020) SCOTTSDALE, AZ – Gridiron BioNutrients™ (OTCQB: GMVP), announces it has taken key steps into expanding its business within the CBD Oil processing space. Gridiron executed a C |
|
| February 5, 2020 |
EX-10.5 7 gmvpex105.htm COMMON STOCK PURCHASE WARRANT EXHIBIT 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE |
|
| February 5, 2020 |
EXHIBIT 10.1 STOCK PURCHASE AGREEMENT THIS AGREEMENT is made and entered into this 24th day of January 2020, by and between Notis Global, Inc. (“Seller”/”NGBL”) a Nevada corporation and Gridiron BioNutrients, Inc. a Nevada corporation (“Purchaser”/”GMVP”) with regard certain capital stock of NGBL. WHEREAS, the Seller is the record owner and holder of certain issued and outstanding shares of capita |
|
| February 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 GridIron BioNutrients, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55852 (Commission File Num |
|
| February 5, 2020 |
10% Original Issue Discount 10% Convertible Redeemable Senior Secured Note Due July 27, 2020 EX-4.1 2 gmvpex41.htm CONVERTIBLE REDEEMABLE SENIOR SECURED NOTE EXHIBIT 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES A |
|
| February 5, 2020 |
EX-10.3 5 gmvpex103.htm SUPPLY AGREEMENT EXHIBIT 10.3 SUPPLY AGREEMENT This Agreement (“the Agreement”), is made by and between EWSD 1, LLC, d/b/a/ SHI FARMS (“Shi Farms”), a Delaware limited liability company and Gridiron BioNutrients, Inc, a Nevada Corporation (“Gridiron”) , each individually “a Party,” and collectively, “the Parties.” WHEREAS Shi Farms grows industrial hemp and wishes to sell h |
|
| January 21, 2020 |
MYYZ / My Cloudz Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 GRIDIRON B |
|
| January 14, 2020 |
MYYZ / My Cloudz Inc NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: November 30, 2019 o o o o o Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K T |
|
| December 17, 2019 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT GridIron Ventures, Inc., a Nevada corporation |
|
| December 17, 2019 |
MYYZ / My Cloudz Inc 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2019 Commission File No. 000-55852 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 36-4797193 (State or other jurisdiction of (I.R.S. Employer incorporati |
|
| November 25, 2019 |
MYYZ / My Cloudz Inc NT 10-K - - NT 10-K NT 10-K 1 gmvpnt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: August 31, 2019 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transi |
|
| August 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 GridIron BioNutrients, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55852 (Commission File Numbe |
|
| July 18, 2019 |
MYYZ / My Cloudz Inc 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 gmvp10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| July 15, 2019 |
MYYZ / My Cloudz Inc NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: May 31, 2019 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transiti |
|
| April 15, 2019 |
MYYZ / My Cloudz Inc FORM 10-Q (Quarterly Report) 10-Q 1 gmvp10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| March 11, 2019 |
GridIron BioNutrients, Inc. 1119 West 1st Ave., Ste. G Spokane, Washington 99021 March 11, 2019 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Jeffrey Gabor, Esq. Re: GridIron BioNutrients, Inc. Registration Statement on Form S-1 (File No. 333-230069) Dear Mr. Gabor: Pursuant to Rule 461(a) of the Securities Act of 1933, as amended, GridIron BioNutrients |
|
| March 5, 2019 |
S-1 1 gmvps1.htm FORM S-1 As filed with the Securities and Exchange Commission on March 4, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 2080 36-4797193 (State or Other Jurisdiction of (Primar |
|
| January 18, 2019 |
MYYZ / My Cloudz Inc FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 GRIDIRON B |
|
| January 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: November 30, 2018 o o o o o Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K T |
|
| December 14, 2018 |
EXHIBIT 10.1 1 2 3 4 5 |
|
| December 14, 2018 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT GridIron Ventures, Inc., a Nevada corporation |
|
| December 14, 2018 |
MYYZ / My Cloudz Inc FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2018 Commission File No. 000-55852 GRIDIRON BIONUTRIENTS, INC. (Exact name of registrant as specified in its charter) Nevada 36-4797193 (State or other jurisdiction of (I.R.S. Employer incorporati |
|
| November 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: August 31, 2018 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Trans |
|
| August 16, 2018 |
EX-3.1.2 3 gmvpex312.htm CERTIFICATE OF AMENDMENT EXHIBIT 3.1.2 |
|
| August 16, 2018 |
EX-3.1.4 5 gmvpex314.htm CERTIFICATE OF CORRECTION EXHIBIT 3.1.4 |
|
| August 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2018 GridIron BioNutrients, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55852 (Commission File Numb |
|
| August 16, 2018 |
Form of Registration Rights Agreement, dated July 30, 2018 EX-10.2 8 gmvpex102.htm FORM OF REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.2 [FORM OF REGISTRATION RIGHTS AGREEMENT] THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 30, 2018 (the “Execution Date”), is entered into by and among GRIDIRON BIONUTRIENTS, INC., a Nevada corporation (the “Company”), and the undersigned buyers (each, a “Buyer” and collectively, the “Buyers”). Capital |
|
| August 16, 2018 |
Form of Warrant, dated July 30, 2018. EX-4.1 6 gmvpex41.htm FORM OF WARRANT EXHIBIT 4.1 [FORM OF WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE |
|
| August 16, 2018 |
EXHIBIT 3.1.3 |
|
| August 16, 2018 |
Form of Securities Purchase Agreement, dated July 30, 2018 EX-10.1 7 gmvpex101.htm FORM OF SECURITIES PURCHASE AGREEMENT EXHIBIT 10.1 [FORM OF SECURITIES PURCHASE AGREEMENT] THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), is entered into as of July 30, 2018 (the “Execution Date”), by and among Gridiron BioNutrients, Inc., a Nevada corporation, with headquarters located at 1119 West 1st Ave., Ste. G, Spokane, Washington 99021 (the “Company”), and the |
|
| August 16, 2018 |
EX-3.1.1 2 gmvpex311.htm CERTIFICATE OF AMENDMENT EXHIBIT 3.1.1 |
|
| July 25, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement GRIDIRON BIONUTRIENTS, INC. (Name of Registrant |
|
| July 24, 2018 |
MYYZ / My Cloudz Inc / Grays Peak Llc - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 GridIron BioNutrients, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 39809D102 (CUSIP Number) Grays Peak LLC c/o GridIron BioNutrients, Inc. 8 The Green, Ste. A Dover, DE 19803 Tel: (302) 288-0670 (Name, Address and Telephone Number of |
|
| July 23, 2018 |
MYYZ / My Cloudz Inc FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 GRIDIRON BIONU |
|
| July 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: May 31, 2018 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transiti |
|
| July 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement GRIDIRON BIONUTRIENTS, INC. (Name of Registrant |
|
| April 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2018 GridIron BioNutrients, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55852 (Commission File Numbe |
|
| April 24, 2018 |
Law Offices of Thomas E. Puzzo, PLLC 3823 44th Ave. NE Seattle, Washington 98105 Telephone: +1 (206) 522-2256 E-mail: [email protected] April 23, 2018 VIA EDGAR Jeffrey Gabor Office of Healthcare & Insurance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: GridIron BioNutrients, Inc. (f/k/a My Cloudz, Inc.) Current Report on Form 8-K/A Filed March 1, 2018 File No. |
|
| April 23, 2018 |
MYYZ / My Cloudz Inc FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 GRIDIRON B |
|
| April 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 39809D102 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: February 28, 2018 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tra |
|
| March 1, 2018 |
8-K/A 1 mycloudz8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Amendment No. 3 to FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2017 GridIron BioNutrients, Inc. (f/k/a My Cloudz, Inc.) (Exact name of registrant as specified in its charter) Nevada |
|
| February 27, 2018 |
8-K 1 gmvp8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2018 GridIron BioNutrients, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000 |
|
| February 21, 2018 |
gmvpex31.htm EXHIBIT 3.1 |
|
| February 21, 2018 |
gmvp8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2018 GridIron BioNutrients, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55852 (Commiss |
|
| February 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Amendment No. 2 to FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2017 My Cloudz, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55852 (Commission Fi |
|
| February 2, 2018 |
Description of Verbal Agreement dated October 9, 2017 by and between My Cloudz, Inc. and Darren Long EXHIBIT 10.7 Description of Verbal Agreement by and between My Cloudz, Inc. and Darren Long My Cloudz, Inc., a Nevada corporation (the “Company”) and Darren Long are parties to an oral contract dated October 9, 2017. Mr. Long, the Chief Executive Officer and Chairman of the Board of Directors of the Company, has provided the Gridiron MVP™ formulations (the “Formulations”) to the Company at no char |
|
| February 2, 2018 |
Law Offices of Thomas E. Puzzo, PLLC 3823 44th Ave. NE Seattle, Washington 98105 Telephone: +1 (206) 522-2256 E-mail: [email protected] February 2, 2018 VIA EDGAR Jeffrey Gabor Office of Healthcare & Insurance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: My Cloudz, Inc. Current Report on Form 8-K Filed October 10, 2017 File No. 000-55852 Dear Mr. Gabor: We res |
|
| February 1, 2018 |
DEF 14C 1 mycloudzdef14c.htm DEF 14C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement MY CLOUDZ, INC. (Name of |
|
| January 22, 2018 |
mycloudzpre14c.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement MY CLOUDZ, INC. (Name of Registrant as Spec |
|
| January 22, 2018 |
MYYZ / My Cloudz Inc FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-55852 MY CLOUDZ, |
|
| January 19, 2018 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 mycloudz8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2018 My Cloudz, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55852 (C |
|
| January 19, 2018 |
Letter from PLS CPA, a Professional Corp., dated January 19, 2018 mycloudzex161.htm EXHIBIT 16.1 PLS CPA, A Professional Corp. t 4725 MERCURY STREET SUITE 210 t SAN DIEGO t CALIFORNIA 92111 t t TELEPHONE (858)722E-5953 t FAX (858) 761-0341 t FAX (858) 764-5480 t E-MAIL [email protected] t January 19, 2018 U.S. Securities & Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen I have read the statements i |
|
| January 19, 2018 |
EXHIBIT 3.1.2 |
|
| January 19, 2018 |
MYYZ / My Cloudz Inc FORM 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2017 Commission File No. 000-55852 MY CLOUDZ, INC. (Exact name of registrant as specified in its charter) Nevada 36-4797193 (State or other jurisdiction of (I.R.S. Employer inco |
|
| January 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55852 NOTIFICATION OF LATE FILING CUSIP NUMBER 62847K102 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: November 30, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tra |
|
| January 3, 2018 |
Law Offices of Thomas E. Puzzo, PLLC 3823 44th Ave. NE Seattle, Washington 98105 Telephone: +1 (206) 522-2256 E-mail: [email protected] January 3, 2018 VIA EDGAR Jeffrey Gabor Office of Healthcare & Insurance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: My Cloudz, Inc. Current Report on Form 8-K Filed October 10, 2017 File No. 000-55852 Dear Mr. Gabor: We resp |
|
| January 3, 2018 |
8-K/A 1 mycloudz8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Amendment No. 1 to FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2017 My Cloudz, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of inco |
|
| January 3, 2018 |
EXHIBIT 10.4 |
|
| December 15, 2017 |
EXHIBIT 3.1.2 |
|
| December 15, 2017 |
MYYZ / My Cloudz Inc FORM 10-K (Annual Report) 10-K 1 mycloudz10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2017 Commission File No. 000-55852 MY CLOUDZ, INC. (Exact name of registrant as specified in its charter) Nevada 36-4797193 (State or other jurisdiction of (I.R.S. |
|
| December 6, 2017 |
EX-10.2 3 mycloudzex102.htm ENDORSEMENT AGREEMENT ADDENDUM I EXHIBIT 10.2 ENDORSEMENT AGREEMENT ADDENDUM I This Endorsement Agreement Addendum I (the “Addendum”) is made and effective November 7, 2017, BETWEEN: National Football League Alumni – Northern California Chapter (“NFLA-NC”), a charitable corporation organized under the laws of California, having its principal office at 1311 Madison Avenu |
|
| December 6, 2017 |
EXHIBIT 10.1 ENDORSEMENT AGREEMENT This Endorsement Agreement (?Agreement?) made October 30, 2017, between National Football League Alumni ? Northern California Chapter (?NFLA-NC?), a charitable corporation organized under the laws of California, having its principal office at 1311 Madison Avenue, Redwood CA 94061; National Football League Alumni, Inc. (?NFLA?), a charitable corporation organized |
|
| December 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2017 My Cloudz, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55852 (Commission File Number) 36-4797 |
|
| December 6, 2017 |
EXHIBIT 99.1 Gridiron BioNutrients? Announces Three Year Endorsement Agreement with the National Football League Alumni (NFLA) Under Pro Football Legends, the Commercial Marketing Arm of the NFL Alumni NEWS PROVIDED BY Gridiron BioNutrients, Inc. Nov 13, 2017, 09:05 ET SPOKANE, Wash., Nov. 13, 2017 /PRNewswire/ - Gridiron BioNutrients? formerly MyCloudz, Inc. (OTC: MYYZ), a nutraceutical innovator |
|
| November 29, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-203373 (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form 10-D ¨ Form N-CSR For Period Ended: August 31, 2017 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report o |
|
| October 24, 2017 |
MYYZ / My Cloudz Inc / Martinho Brian - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 My Cloudz, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 62847K102 (CUSIP Number) Brian Martinho 1119 West 1st Ave., Ste. G Spokane, Washington 99021 Tel: (800) 570-0438 (Name, Address and Telephone Number of Person Authorized to Recei |
|
| October 24, 2017 |
MYYZ / My Cloudz Inc / Long Darren - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 My Cloudz, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 62847K102 (CUSIP Number) Darren Long 1119 West 1st Ave., Ste. G Spokane, Washington 99201 Tel: (800) 570-0438 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| October 24, 2017 |
MYYZ / My Cloudz Inc / Orr Timothy - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 My Cloudz, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 62847K102 (CUSIP Number) Timothy Orr 1119 West 1st Ave., Ste. G Spokane, Washington 99201 Tel: (800) 570-0438 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| October 10, 2017 |
Indemnification Agreement dated October 9, 2017, by and between My Cloudz, Inc. and Darren Long. (1) EXHIBIT 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the ?Agreement?) is made as of October 9, 2017, by and between My Cloudz, Inc., a Nevada corporation (the ?Company?), and Darren Long (the ?Indemnitee?). RECITALS The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and key employees, the significant increases i |
|
| October 10, 2017 |
GRIDIRON BIONUTRIENTS, INC. Financial Statements August 31, 2017 Table of Contents EX-99.1 6 mycloudzex991.htm FINANCIAL STATEMENTS EXHIBIT 99.1 GRIDIRON BIONUTRIENTS, INC. Financial Statements August 31, 2017 Table of Contents Page Report of Independent Registered Accounting Firm F-2 Balance Sheet as of August 31, 2017 F-3 Statement of Operations for the Period of July 20, 2017 (Inception) to August 31, 2017 F-4 Statement of Changes in Stockholders’ Deficit for the Period of Ju |
|
| October 10, 2017 |
EX-99.2 7 mycloudzex992.htm UNAUDITED PRO FORMA EXHIBIT 99.2 MY CLOUDZ, INC. (Gridiron Bionutrients, Inc.) UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEETS AS OF AUGUST 31, 2017 My Cloudz, Inc. Gridiron Bionutrients, Inc. Adjustments Pro-Forma Combined Assets Current Assets Cash $ 4,877 $ 25 $ - $ 4,902 Total Current Assets 4,877 25 - 4,902 Trademarks - 2.800 - 2,800 Total Assets $ 4,877 $ 2, |
|
| October 10, 2017 |
Indemnification Agreement dated October 9, 2017, by and between My Cloudz, Inc. and Timothy Orr. (1) EX-10.2 4 mycloudzex102.htm INDEMNIFICATION AGREEMENT EXHIBIT 10.2 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”) is made as of October 9, 2017, by and between My Cloudz, Inc., a Nevada corporation (the “Company”), and Timothy Orr (the “Indemnitee”). RECITALS The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, o |
|
| October 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 MY CLOUDZ, INC. (Exact name of Registrant as specified in its charter) Nevada 36-4797193 (State of Incorporation) (I.R.S. Employer Identification No.) 430/23 Moo 12, Nongprue, Banglamung Chonburi |
|
| October 10, 2017 |
8-K 1 mycloudz8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2017 My Cloudz, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-55852 (Co |
|
| October 10, 2017 |
EXHIBIT 10.3 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the ?Agreement?) is made as of October 9, 2017, by and between My Cloudz, Inc., a Nevada corporation (the ?Company?), and Brian Martinho (the ?Indemnitee?). RECITALS The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and key employees, the significant increase |
|
| October 10, 2017 |
EX-2.1 2 mycloudzex21.htm SHARE EXCHANGE AGREEMENT EXHIBIT 2.1 SHARE EXCHANGE AGREEMENT THIS SHARE EXCHANGE AGREEMENT (the “Agreement”) dated as of October 9, 2017 is entered into by and among My Cloudz, Inc., a Nevada corporation (“My Cloudz”), and GridIron BioNutrients, Inc., a Nevada corporation (“GridIron BioNutrients”), and the shareholders of GridIron BioNutrients listed on Annex A to this A |
|
| September 7, 2017 |
8-K 1 mycloudz8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event ): September 5, 2017 My Cloudz, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-203373 (Commiss |
|
| July 24, 2017 |
MYYZ / My Cloudz Inc FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 333-203373 MY CLOUDZ, INC. (Exact name |
|
| July 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-203373 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form N-SAR ? Form 10-D ? Form N-CSR For Period Ended: May 31, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on F |
|
| June 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2017 My Cloudz, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-203373 (Commission File Number) 36-479719 |
|
| April 14, 2017 |
MYYZ / My Cloudz Inc 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 mycloudz10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 3 |
|
| January 17, 2017 |
MYYZ / My Cloudz Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 333-203373 MY CLOUDZ, INC. (Exact |
|
| December 6, 2016 |
MYYZ / My Cloudz Inc 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended August 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 333-203373 My Cloudz, Inc. (E |
|
| November 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-203373 (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form 10-D ? Form N-CSR For Period Ended: August 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report o |
|
| October 7, 2016 |
MYYZ / My Cloudz Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 333-203373 MY CLOUDZ, INC. (Exact name |
|
| September 26, 2016 |
MYYZ / My Cloudz Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 29, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 333-203373 MY CLOUDZ, INC. (Exact |
|
| February 12, 2016 |
MYYZ / My Cloudz Inc 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 mycloudz10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 3 |
|
| January 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2016 (January 20, 2016) Date of Report (Date of earliest event reported) My Cloudz, Inc. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 333-2 |
|
| January 29, 2016 |
EX-16.1 2 mycloudzex161.htm LETTER EXHIBIT 16.1 January 29, 2016 U.S. Securities and Exchange Commission Office of the Chief Accountant 100F Street Northeast Washington, DC 20549-2000 RE: My Cloudz, Inc. File No. 333-203373 Dear Sir or Madam: We have read Item 4.01 of Form 8-K/A dated January 29, 2016 of My Cloudz, Inc. ("the Registrant") and are in agreement with the statements contained therein |
|
| January 25, 2016 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2016 (January 20, 2016) Date of Report (Date of earliest event reported) My Cloudz, Inc. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 333-203 |
|
| December 23, 2015 |
My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thialand My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thialand December 23, 2015 To: Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Attention: Mr. Austin Mitchell Washington D.C. 20549 Phone (202) 551-3574 From: My Coudz, Inc. File Number 333-203373 RE: Request for Acceleration of the Effective Date. My Cloudz, Inc. ("the Company") hereby requests f |
|
| December 22, 2015 |
My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thialand My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thialand December 22, 2015 To: Security and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Attention: Mr. Austin Mitchell Washington D.C. 20549 Phone (202) 551-3574 From: My Coudz, Inc. File Number 333-203373 RE: Request for Acceleration of the Effective Date. My Cloudz, Inc. ("the Company") hereby requests for |
|
| December 7, 2015 |
As filed with the Securities and Exchange Commission on December 7, 2015 Registration No. |
|
| December 7, 2015 |
My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thailand My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thailand Security and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington D.C. 20549-4628 December 7, 2015 Re: My Cloudz, Inc. Registration Statement Form S-1/Amendment #3 File Number 333-203373 Filed: June 22, 2015 Attention: Ms. Katherine Wray Phone (202) 551-3483 My Cloudz, Inc. (the "Company") has rec |
|
| June 22, 2015 |
My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thailand My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thailand June 22, 2015 Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington D.C. 20549-4628 Re: My Cloudz, Inc. Registration Statement Form S-1/Amendment #1 File Number 333-203373 Filed: May 29, 2015 Attention: Ms. Katherine Wray Phone (202) 551-3483 My Cloudz, Inc. (the “Company”) has recei |
|
| June 22, 2015 |
As filed with the Securities and Exchange Commission on June 22, 2015 Registration No. |
|
| May 29, 2015 |
My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thialand CORRESP 12 filename12.htm My Cloudz, Inc. 430/23 Moo 12 Nongprue, Banglamung Chonburi 20150 Thialand Security and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington D.C. 20549-4628 May 29, 2015 Re: My Cloudz, Inc. Registration Statement Form S-1 File Number 333-203373 Filed: April 13, 2015 Attention: Ms. Katherine Wray Phone (202) 551-3483 My Cloudz, Inc. (the “Company |
|
| May 29, 2015 |
S-1/A 1 mycloudzs1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on May 29, 2015 Registration No. 333-203373 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 My Cloudz, Inc. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of in |
|
| May 29, 2015 |
EXHIBIT 3(i) CORPORATE CHARTER I, ROSS MILLER, the duly elected and qualified Nevada Secretary of State, do hereby certify that MY CLOUDZ, INC. |
|
| May 29, 2015 |
BY-LAWS My Cloudz, Inc. A Nevada Corporation ARTICLE I - OFFICES EX-3.2 3 mycloudzex3ii.htm BY-LAWS EXHIBIT 3(ii) BY-LAWS OF My Cloudz, Inc. A Nevada Corporation ARTICLE I - OFFICES The registered office of the Corporation in the State of Nevada shall be located in the City and State designated in the Articles of Incorporation. The Corporation may also maintain offices at such other places within or without the State of Nevada as the Board of Directors may, fro |
|
| April 13, 2015 |
EXHIBIT 3(II) |
|
| April 13, 2015 |
S-1 1 mycloudzs1.htm FORM S-1 As filed with the Securities and Exchange Commission on April 13, 2015 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 My Cloudz, Inc. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 7374 |
|
| April 13, 2015 |
EX-3.1 2 mycloudzex3i.htm ARTICLES OF INCORPORATION EXHIBIT 3(I) 1 2 |
